Julian Olea

Julian Olea

Auto-generated profile, based on publicly available information

Julian Olea

University of Southern California 3 Division of Hematology, Health Sciences Campus Los Angeles, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
JOJulian Olea
Julian Olea
CCClaudia S Villa Celi
Claudia S Villa Celi
HDHoma Dadrastoussi
Homa Dadrastoussi
KWKaijin Wu
Kaijin Wu
KKKevin Kelly
Kevin Kelly
Purpose: Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone (Dex) and bortezomib (BZ) and define the tumor immune microenvironment (TiME) in patients with multiple myeloma treated with this regimen. Patients and Methods: Patients with relapsed/refractory multiple myeloma (n = 14) were enrolled in a phase Ib clinical trial (ClinicalTrials.gov: NCT02514382) of three escalating PELA doses administered on Days 1, 2, 8, 9, 15, and 16. Patients received 40 mg Dex and 1.5 mg/m2 BZ on Days 1, 8, and 15. Cycles were repeated every 28 days. Pre- and posttreatment bone marrow specimens (IHC, n = 9; imaging mass cytometry, n = 6) and peripheral blood samples were collected for analysis (flow cytometry, n = 5; T-cell receptor clonality, n = 7; cytokine assay, n = 7). Results: PELA/BZ/Dex was well-tolerated in all patients. Treatment-emergent toxicities were transient, and no dose-limiting toxicities occurred. Six (55%) of 11 response-evaluable patients showed decreased paraprotein. Treatment increased T and natural killer cell activation, inflammatory cytokine release, and programmed death-ligand 1 expression in bone marrow. Compared with nonresponders, responders had higher reovirus protein levels, increased cytotoxic T-cell infiltration posttreatment, cytotoxic T cells in significantly closer proximity to multiple myeloma cells, and larger populations of a novel immune-primed multiple myeloma phenotype (CD138+ IDO1+HLA-ABCHigh), indicating immunomodulation. Conclusions: PELA/BZ/Dex is well-tolerated and associated with anti–multiple myeloma activity in a subset of responding patients, characterized by immune reprogramming and TiME changes, warranting further investigation of PELA as an immunomodulator.

1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Acute myeloid leukemia (AML) remains defined by therapeutic resistance, adverse genetic heterogeneity, and poor long-term survival, underscoring the need for mechanistically informed regimens that exploit core stress-adaptation liabilities. Polo-like kinase 1 (PLK1) is a central regulator of replication recovery and mitotic progression, yet direct PLK1 inhibitors have been limited by tolerability and incomplete target suppression. Here, we define a clinically actionable strategy that functionally targets PLK1 by combining inhibition of the AAA+ ATPase p97/valosin-containing protein with the hypomethylating agent decitabine (DAC). Using AML cell lines, primary patient specimens, and an orthotopic in vivo model, we show that the clinically relevant p97 inhibitor CB-5339 induces proteotoxic and replication stress, activates the unfolded protein response, and triggers apoptosis. Formal synergy analyses demonstrate that CB-5339 and DAC cooperate across molecular subtypes, including FLT3-ITD+, KMT2A-rearranged, and TP53-mutant AML, to reduce cell viability at pharmacologically relevant concentrations. Transcriptomic, biochemical, and genetic studies identify synergistic suppression of PLK1 as a central consequence of combination treatment, converting stress-dependent PLK1 reliance into a therapeutic vulnerability. Consistent with this mechanism, PLK1 knockdown phenocopies the antileukemic effects of the combination and enhances sensitivity to both agents. In vivo, CB-5339/DAC is well tolerated, significantly prolongs survival, reduces leukemic burden, and suppresses PLK1 in bone marrow blasts. Together, these data establish p97 inhibition as a rational means to exploit replication and proteotoxic stress in AML and provide strong rationale for clinical evaluation of CB-5339 plus DAC in high-risk disease. Significance: This study defines a clinically actionable strategy to overcome therapeutic resistance in AML by functionally suppressing PLK1 through combined p97 inhibition and hypomethylating therapy. By exploiting convergent proteotoxic and replication stress, the regimen produces robust, well-tolerated antileukemic activity across high-risk genetic subtypes, supporting near-term clinical evaluation.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Figure S4. Gene modulation overlap between MOLM-13 and MV4-11 cells.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Figure S2. CB-5339 and DAC synergize to trigger apoptosis.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
PLK1 is a key pharmacodynamic target of the CB-5339/DAC combination. A, Targeted PLK1 knockdown impairs AML cell proliferation. MOLM-13 cells were transduced with nontargeted control of PLK1-targeted lentiviral shRNA. Knockdown efficiency was determined by immunoblotting. Cell numbers were quantified for both conditions at 48 hours after lentiviral transduction. N = 3 ± SD; * indicates a significant difference from control shRNA, P < 0.005. B and C, Effects of targeted PLK1 knockdown on sensitivity to CB-5339 and DAC. MOLM-13 cells were infected with lentiviral nontargeted control or PLK1-targeted shRNA. Cells were treated with the indicated concentrations of CB-5339 and DAC. Cell viability was determined by MTT assay. N = 3 ± SD; * indicates a significant difference from control shRNA, P < 0.05. D, High PLK1 expression is associated with resistance to hypomethylating therapy. Within the ELN2022 adverse-risk group, patients with AML were stratified based on PLK1 levels comparing PLK1-low expression (bottom 25%) and PLK1-high expression (top 25%). Hypomethylating therapy response (azacitidine) is shown as an AUC in which higher values indicate greater resistance. Each dot represents an individual patient. Statistical significance was determined using a two-sided Wilcoxon rank-sum test (*, P = 0.05). E, PLK1 is a determinant of sensitivity to the CB-5339/DAC combination. MOLM-13 cells transduced with nontargeted control shRNA or PLK1-targeted shRNA lentiviral vectors were treated with 250 nmol/L CB-5339, 500 nmol/L DAC, or both drugs for 72 hours. The impact of drug treatment on cell viability was determined by MTT assay. N = 3 ± SD; * indicates a significant difference from control shRNA, P < 0.005. F, Overexpression of PLK1 promotes resistance to CB-5339 and DAC. PLK1 was overexpressed in MOLM-13 cells using PLK1-Myc-DDK lentiviral particles. Overexpression efficiency was assessed by immunoblotting. Vector control and PLK1-overexpressing cells were treated with 200 nmol/L CB-5339, 300 nmol/L DAC, and the combination for 72 hours. The effects of drug treatment on cell viability were quantified for each experimental condition by MTT assay. Mean ± SD, n = 3. * indicates a significant difference from vector control cells, P < 0.05.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Acute myeloid leukemia (AML) remains defined by therapeutic resistance, adverse genetic heterogeneity, and poor long-term survival, underscoring the need for mechanistically informed regimens that exploit core stress-adaptation liabilities. Polo-like kinase 1 (PLK1) is a central regulator of replication recovery and mitotic progression, yet direct PLK1 inhibitors have been limited by tolerability and incomplete target suppression. Here, we define a clinically actionable strategy that functionally targets PLK1 by combining inhibition of the AAA+ ATPase p97/valosin-containing protein with the hypomethylating agent decitabine (DAC). Using AML cell lines, primary patient specimens, and an orthotopic in vivo model, we show that the clinically relevant p97 inhibitor CB-5339 induces proteotoxic and replication stress, activates the unfolded protein response, and triggers apoptosis. Formal synergy analyses demonstrate that CB-5339 and DAC cooperate across molecular subtypes, including FLT3-ITD+, KMT2A-rearranged, and TP53-mutant AML, to reduce cell viability at pharmacologically relevant concentrations. Transcriptomic, biochemical, and genetic studies identify synergistic suppression of PLK1 as a central consequence of combination treatment, converting stress-dependent PLK1 reliance into a therapeutic vulnerability. Consistent with this mechanism, PLK1 knockdown phenocopies the antileukemic effects of the combination and enhances sensitivity to both agents. In vivo, CB-5339/DAC is well tolerated, significantly prolongs survival, reduces leukemic burden, and suppresses PLK1 in bone marrow blasts. Together, these data establish p97 inhibition as a rational means to exploit replication and proteotoxic stress in AML and provide strong rationale for clinical evaluation of CB-5339 plus DAC in high-risk disease.Significance:This study defines a clinically actionable strategy to overcome therapeutic resistance in AML by functionally suppressing PLK1 through combined p97 inhibition and hypomethylating therapy. By exploiting convergent proteotoxic and replication stress, the regimen produces robust, well-tolerated antileukemic activity across high-risk genetic subtypes, supporting near-term clinical evaluation.